Sign in
GLSI Stock Price, Chart, Stats & News
Greenwich LifeSciences, Inc.
Save
Greenwich LifeSciences, Inc. (GLSI) does not currently pay a dividend.
273.01M
Market cap
–
Current P/E
–
Forward P/E
GLSI chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -511.58% |
ROE | -1042.76% |
D/E | – |
Interest coverage ratio | – |
GLSI valuation
P/E | – |
P/S | – |
P/B | 139.41x |
P/CF | -35.46x |
P/FCF | -36.01x |
P/OCF | -35.46x |
PEG | 2.13x |
EV multiple | -16.05x |
About
Greenwich LifeSciences, Inc. functions as a clinical-stage biopharmaceutical company, dedicated to developing innovative cancer immunotherapies. These treatments are primarily focused on breast cancer and other HER2/neu-positive malignancies. Its flagship therapeutic candidate is GP2, an immunotherapy which has successfully completed its Phase IIb clinical trials.
Similar securities
Based on sector and market capitalization
Report issue